Are you weening yourself off a compounded version of the drug? Considering switching insurers in order to keep your ...

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

California Healthline: Silence On E. Coli Outbreak Highlights How Trump Team’s Changes Undermine Food Safety Food ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Drugmakers are introducing discounts and lower-cost options for consumers who have to pay for GLP-1 drugs out of pocket. News outlets look at the trend in pricing for drugs like Wegovy and Zepbound.

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.